肥胖是早期类风湿关节炎临床结局与治疗反应不佳的强预测因素:SWEFOT 试验结果
该研究基于瑞典 SWEFOT 试验中 260 例早期类风湿关节炎(RA)患者,按基线体重指数(BMI)分为肥胖、超重和正常三组,评估 24 个月内疾病活动度、功能、疼痛和影像学损伤差异。结果显示,肥胖与 24 个月内更差的临床结局相关,肥胖患者未缓解的调整 OR 为 5.2(95%CI 1.8–15.2),但肥胖与影像学进展无独立关联。
要点
- 肥胖与 24 个月内 DAS28、HAQ 和 VAS 疼痛更差相关,肥胖 vs 正常 p<0.001。
- 肥胖患者 24 个月未缓解风险更高,调整 OR 5.2(95%CI 1.8–15.2)。
- 女性、吸烟和 HAQ 也是未缓解的独立预测因素,肥胖与影像学进展无独立关联。
核心结论
- 在反映当前标准治疗的早期 RA 试验中,肥胖与性别、吸烟和功能受损一样,显著降低达到良好临床结局(包括缓解)的机会。
研究设计与样本
- 基于瑞典药物疗法试验(SWEFOT),260 例早期 RA 患者有 BMI 数据,按肥胖(BMI>30,n=43)、超重(BMI=25–29.9,n=74)和正常(BMI<25,n=143)分组。
- 采用非参数检验比较 24 个月内 DAS28、HAQ、VAS 疼痛和影像学损伤差异,并用单变量和多变量 logistic 回归评估 24 个月 EULAR 未缓解(DAS28≥2.6)的预测因素。
主要发现
- 基线肥胖与 24 个月内更差的连续量表临床结局相关:末次访视 DAS28、HAQ 和 VAS 疼痛,肥胖 vs 正常 p<0.001,肥胖 vs 超重 p<0.05。
- 肥胖患者相比非肥胖患者 24 个月未缓解的调整 OR 为 5.2(95%CI 1.8–15.2)。
- 其他独立预测因素包括女性(aOR 2.6;95%CI 1.1–5.8)、当前吸烟(aOR 2.6;95%CI 1.1–6.3)和 HAQ 每单位增加(aOR 1.9;95%CI 1.1–3.4)。
- 在血清阳性和血清阴性患者中模式相似,在甲氨蝶呤应答者和 3 个月时随机加用柳氮磺吡啶+羟氯喹亚组中模式相似,但加用英夫利西单抗亚组不显著。
- 肥胖与影像学进展无独立关联。
临床怎么用
- 对早期 RA 患者应评估 BMI,肥胖提示临床缓解和治疗反应可能更差。
- 考虑将生活方式调整(包括体重管理)作为 RA 综合管理的重要组成部分。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this paper was to analyse the impact of obesity, in addition to known predictors, on disease outcome in early rheumatoid arthritis (RA). METHODS: Body mass index (BMI) was available in 260 patients from the Swedish pharmacotherapy trial (SWEFOT). Differences in disease activity (DAS28), functional impairment (HAQ), pain (Visual Analogue Scale, VAS-pain) and radiographic damage were evaluated over 24 months between BMI categories (obese BMI >30, n=43; overweight BMI=25-29.9, n=74; normal BMI <25, n=143) using non-parametric testing. Predictors of European League Against Rheumatism non-remission (DAS28 ≥2.6) at 24 months of follow-up were evaluated using binary univariate and multivariate logistic regression. RESULTS: Obesity at baseline was associated with worse continuous-scale clinical outcomes over 24 months (DAS28, HAQ and VAS-pain at last visit: obese vs normal: p<0.001; obese vs overweight: p<0.05). Furthermore, obese patients compared with non-obese patients had significantly greater odds of non-remission at 24 months (adjusted OR (aOR) 5.2; 95% CI 1.8 to 15.2). Other independent predictors were female sex (aOR 2.6; 95% CI 1.1 to 5.8), current smoking (aOR 2.6; 95% CI 1.1 to 6.3) and HAQ (per-unit increase, aOR 1.9; 95% CI 1.1 to 3.4). The pattern was similar among seropositive and seronegative patients; and in the subgroups of methotrexate responders and patients randomised at 3 months to add-on of sulfasalazine+hydroxychloroquine, although not significant with add-on of infliximab. Obesity had no independent association to radiographic progression. CONCLUSIONS: In this early RA trial reflecting today's standard treatment, obesity, in addition to sex, smoking and functional impairment strongly lowered the chance of attaining good clinical outcomes, including remission, today's treatment goal. This highlights the importance of considering lifestyle modification as one of the cornerstones of RA care. TRIAL REGISTRATION NUMBER: NCT00764725; Post-results. WHO database at the Karolinska University Hospital: CT20080004.
引用
- Levitsky A, Brismar K, Hafström I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2017. PMID: 28879052. doi:10.1136/rmdopen-2017-000458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。